Hepatic resection versus transarterial lipiodol chemoembolization as the initial treatment for large, multiple, and resectable hepatocellular carcinomas: A prospective nonrandomized analysis

Radiology

Volumn 259, Issue 1, 2011, Pages 286-295

  Luo, Jun ^a   Peng, Zhen Wei ^a   Guo, Rong Ping ^a   Zhang, Ya Qi ^a   Li, Jin Qing ^a   Chen, Min Shan ^a   Shi, Ming ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; EPIRUBICIN; GADODIAMIDE; IODINATED POPPYSEED OIL; LIPIODOL ULTRAFLUIDE; MITOMYCIN C; UNCLASSIFIED DRUG; ETHIODIZED OIL; HEMOSTATIC AGENT;

ABLATION THERAPY; ADULT; AGED; ARTICLE; ASCITES; BILE LEAKAGE; CANCER GROWTH; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HUMAN; INTERMETHOD COMPARISON; JAUNDICE; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER RESECTION; LUNG COMPLICATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; OVERALL SURVIVAL; PLEURA EFFUSION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PAIN; POSTOPERATIVE VOMITING; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SEPSIS; SURVIVAL RATE; TUMOR VOLUME; WOUND HEALING IMPAIRMENT; CARCINOMA, HEPATOCELLULAR; CHINA; EPIDEMIOLOGY; INTRAARTERIAL DRUG ADMINISTRATION; LIVER NEOPLASMS; MIDDLE AGED; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; SURVIVAL; TREATMENT OUTCOME;

CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CHINA; ETHIODIZED OIL; FEMALE; HEMOSTATICS; HEPATECTOMY; HUMANS; INJECTIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79953004517     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.10101072     Document Type: Article

References (30)

1. Bruix J, Sherman M;Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42(5):1208-1236.
2. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 2002;235(3):373-382. (Pubitemid 34183888)
3. Yamamoto J, Kosuge T, Takayama T, et al. Recurrence of hepatocellular carcinoma after surgery. Br J Surg 1996;83(9):1219-1222. (Pubitemid 26290448)
4. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30(6):1434-1440.
5. Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000;32(6):1224-1229.
6. Wu CC, Cheng SB, Ho WM, Chen JT, Liu TJ, P'eng FK. Liver resection for hepatocellular carcinoma in patients with cirrhosis. Br J Surg 2005;92(3):348-355.
7. Ercolani G, Grazi GL, Ravaioli M, et al. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg 2003;237(4):536-543. (Pubitemid 38176435)
8. Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg 2006;243(2):229-235. (Pubitemid 43185442)
9. Pawlik TM, Izzo F, Cohen DS, Morris JS, Curley SA. Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol 2003;10(9):1059-1069. (Pubitemid 40486830)
10. Ishizawa T, Hasegawa K, Aoki T, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008;134(7):1908-1916. (Pubitemid 351783260)
11. Ho MC, Huang GT, Tsang YM, et al. Liver resection improves the survival of patients with multiple hepatocellular carcinomas. Ann Surg Oncol 2009;16(4):848-855.
12. Liu CL, Fan ST, Lo CM, Ng IO, Poon RT, Wong J. Hepatic resection for bilobar hepatocellular carcinoma: is it justified? Arch Surg 2003;138(1):100-104.
13. Wang BW, Mok KT, Liu SI, et al. Is hepatectomy beneficial in the treatment of multinodular hepatocellular carcinoma? J Formos Med Assoc 2008;107(8):616-626.
14. Ruzzenente A, Capra F, Pachera S, et al. Is liver resection justified in advanced hepatocellular carcinoma? Results of an observational study in 464 patients. J Gastrointest Surg 2009;13(7):1313-1320.
15. Lee HS, Kim KM, Yoon JH, et al. Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virusendemic area: a prospective cohort study. J Clin Oncol 2002;20(22):4459-4465. (Pubitemid 35334758)
16. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35(3):421-430. (Pubitemid 32844200)
17. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5(6):649-655. (Pubitemid 13149996)
18. Shi M, Guo RP, Lin XJ, et al. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg 2007;245(1):36-43. (Pubitemid 46035433)
19. Couinaud C. Contribution of anatomical research to liver surgery [in French]. Fr Med 1956;19(5):5-12.
20. Shi M, Chen JA, Lin XJ, et al. Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China. World J Gastroenterol 2010;16(2):264-269.
21. Zhang YJ, Liang HH, Chen MS, et al. Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial. Radiology 2007;244(2):599-607.
22. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205-216.
23. Shi M, Zhang CQ, Zhang YQ, Liang XM, Li JQ. Micrometastases of solitary hepatocellular carcinoma and appropriate resection margin. World J Surg 2004;28(4):376-381. (Pubitemid 38525871)
24. Lai EC, You KT, Ng IO, Shek TW. The pathological basis of resection margin for hepatocellular carcinoma. World J Surg 1993;17(6):786-790; discussion 791.
25. Otto G, Herber S, Heise M, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplan tation in hepatocellular carcinoma. Liver Transpl 2006;12(8):1260-1267. (Pubitemid 44194595)
26. Millonig G, Graziadei IW, Freund MC, et al. Response to preoperative chemoemboliza tion correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007;13(2):272-279. (Pubitemid 46351654)
27. Chua TC, Liauw W, Saxena A, et al. Systematic review of neoadjuvant transarte rial chemoembolization for resectable hepatocellular carcinoma. Liver Int 010;30(2):166-174.
28. Ernst O, Sergent G, Mizrahi D, Delemazure O, Paris JC, L'Herminé C. Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: comparison of planned periodic chemoembolization and chemoembolization based on tumor response. AJR Am J Roentgenol 1999;172(1):59-64. (Pubitemid 29028431)
29. Nishimine K, Uchida H, Matsuo N, et al. Segmental transarterial chemoembolization with Lipiodol mixed with anticancer drugs for nonresectable hepatocellular carcinoma: follow-up CT and therapeutic results. Cancer Chemother Pharmacol 1994;33(Suppl):S60-S68. (Pubitemid 24147968)
30. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007;30(1):6-25. (Pubitemid 44900485)